Calabash Brothers: Obtained the registration certificate for inhalation of ipratropium bromide solution medicine.

The announcement by Huluo Wa stated that they recently received the Drug Registration Certificate for the inhaled solution of ipratropium bromide approved and issued by the National Medical Products Administration. The specifications are 2ml: 0.25mg and 2ml: 0.5mg, and it is approved to be considered as passing the evaluation of generic drug quality and efficacy consistency. This medicine can be used for treating asthma, chronic obstructive pulmonary disease, etc. As of the disclosure date of the announcement, 29 domestic companies have been approved for production. The company has accumulated research and development expenses of 5.9089 million yuan for this product. However, the sales performance of the medicine is affected by factors such as policies and the market, which brings uncertainty.